IFP Advisors Inc Has $390,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

IFP Advisors Inc lowered its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 7.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,768 shares of the biotechnology company’s stock after selling 1,745 shares during the period. IFP Advisors Inc’s holdings in Arrowhead Pharmaceuticals were worth $390,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Handelsbanken Fonder AB boosted its stake in Arrowhead Pharmaceuticals by 15.4% in the fourth quarter. Handelsbanken Fonder AB now owns 41,200 shares of the biotechnology company’s stock valued at $775,000 after acquiring an additional 5,500 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its stake in Arrowhead Pharmaceuticals by 40.5% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 112,858 shares of the biotechnology company’s stock valued at $2,122,000 after acquiring an additional 32,551 shares during the last quarter. Rhumbline Advisers boosted its stake in Arrowhead Pharmaceuticals by 2.1% in the fourth quarter. Rhumbline Advisers now owns 380,344 shares of the biotechnology company’s stock valued at $7,150,000 after acquiring an additional 7,912 shares during the last quarter. Van ECK Associates Corp boosted its stake in Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 1,250 shares during the last quarter. Finally, Empowered Funds LLC bought a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $268,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ:ARWR opened at $18.91 on Friday. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $17.05 and a 12 month high of $36.72. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The company’s fifty day simple moving average is $19.60 and its 200 day simple moving average is $20.72. The firm has a market cap of $2.38 billion, a price-to-earnings ratio of -3.66 and a beta of 0.95.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). As a group, research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 27,167 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.83, for a total value of $538,721.61. Following the sale, the chief financial officer now directly owns 473,433 shares in the company, valued at approximately $9,388,176.39. The trade was a 5.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Adeoye Y. Olukotun sold 2,850 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, December 27th. The shares were sold at an average price of $20.00, for a total transaction of $57,000.00. Following the completion of the sale, the director now owns 36,740 shares in the company, valued at $734,800. The trade was a 7.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 147,432 shares of company stock worth $2,957,986 over the last ninety days. Company insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

ARWR has been the topic of a number of recent research reports. B. Riley reaffirmed a “buy” rating and issued a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Sanford C. Bernstein reduced their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research note on Friday, November 29th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $41.44.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.